ClinicalTrials.gg
CompletedNCT03375138Updated Jul 24, 2019

A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes

A Phase 1 interventional study of belatacept in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2018, 8 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study compares the movement of Belatacept drug products, whose active pharmaceutical ingredient has been manufactured by 2 different processes, into, through and out of the body (pharmacokinetics/PK) of healthy volunteers. Eligible participants will be randomly assigned to one of two groups, and will receive a single dose of a belatacept product once during a 4-day stay at a study site.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Healthy participants, determined by medical history, physical examination, (ECGs) and clinical laboratory tests.
  • Weight between 60.0 to 100.0 kg, inclusive.
  • (BMI) of 18.0 to 30.0 kg/m2, inclusive.
  • Women of (WOCBP) must have a negative pregnancy test within 24 hours prior to the start of study treatment.
  • WOCBP must agree to follow instructions for method(s) of for the duration of treatment and for a total of 80 days after treatment ends.
  • Women must not be breastfeeding.
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and for a total of 140 days after treatment ends. In addition, male participants must not donate sperm during this time.

Exclusion criteria

Exclusion Criteria:

  • Participants with active tuberculosis (TB) requiring treatment; a history of active or latent TB without documented adequate therapy; or with current clinical, radiographic or laboratory evidence fo active or latent TB.
  • History of shingles (herpes zoster).
  • Personal or strong family history of cancer.
  • Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study treatment administration.
  • Any known or suspected disorder.

Other protocol defined inclusion/exclusion criteria could apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Process E PPQ belatacept

    10 mg/kg, single dose by intravenous (IV) infusion.

    Drug: belatacept

  • Experimental
    Process C belatacept

    10 mg/kg, single dose by intravenous (IV) infusion.

    Drug: belatacept

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)).

    Measured by plasma concentration.

    Time frame: Up to day 57

  2. Maximum observed serum concentration (Cmax).

    Measured by plasma concentration.

    Time frame: Up to day 57

Secondary outcomes

  1. Incidence of non-serious Adverse Events (AEs).

    Safety and tolerability as measured by incidence of non-serious AEs.

    Time frame: Up to 71 days.

  2. Incidence of Serious Adverse Events (SAEs).

    Safety and tolerability as measured by incidence of SAEs.

    Time frame: Up to 71 days.

  3. Incidence of Adverse Events (AEs) leading to discontinuation.

    Safety and tolerability as measured by incidence of AEs leading to discontinuation.

    Time frame: Up to 71 days.

  4. Number of participants with vital sign abnormalities.

    Time frame: Up to 71 days.

  5. Number of participants with physical examination abnormalities.

    Time frame: Up to 71 days.

  6. Number of participants with clinical laboratory abnormalities.

    Time frame: Up to 71 days.

  7. Number of participants with electrocardiogram (ECG) abnormalities.

    Time frame: Up to 71 days.

07

Study locations

2 sites
  • PPD Austin Clinic
    Austin, Texas 78744, United States
  • Covance, Inc.
    Dallas, Texas 75247, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in May 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 15, 2017
StartActual
Dec 4, 2017
Primary completionActual
May 8, 2018
CompletionActual
Apr 2, 2019
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03375138
Responsible party
Sponsor
First posted
Dec 15, 2017
Start date
Dec 4, 2017
Primary completion
May 8, 2018
Completion
Apr 2, 2019
Last update
Jul 24, 2019

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion